Richard D Baird
Overview
Explore the profile of Richard D Baird including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
2196
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Tamborero D, Dienstmann R, Rachid M, Boekel J, Lopez-Fernandez A, Jonsson M, et al.
Nat Cancer
. 2022 Apr;
3(5):649.
PMID: 35449310
No abstract available.
12.
Choudhury A, Higano C, de Bono J, Cook N, Rathkopf D, Wisinski K, et al.
Clin Cancer Res
. 2022 Mar;
28(11):2257-2269.
PMID: 35247924
Purpose: To characterize safety and tolerability of the selective PI3Kβ inhibitor AZD8186, identify a recommended phase II dose (RP2D), and assess preliminary efficacy in combination with abiraterone acetate or vistusertib....
13.
Tamborero D, Dienstmann R, Rachid M, Boekel J, Lopez-Fernandez A, Jonsson M, et al.
Nat Cancer
. 2022 Feb;
3(2):251-261.
PMID: 35221333
There is a growing need for systems that efficiently support the work of medical teams at the precision-oncology point of care. Here, we present the implementation of the Molecular Tumor...
14.
Hudecova I, Smith C, Hansel-Hertsch R, Chilamakuri C, Morris J, Vijayaraghavan A, et al.
Genome Res
. 2021 Dec;
32(2):215-227.
PMID: 34930798
Current evidence suggests that plasma cell-free DNA (cfDNA) is fragmented around a mode of 166 bp. Data supporting this view has been mainly acquired through the analysis of double-stranded cfDNA....
15.
Kingston B, Cutts R, Bye H, Beaney M, Walsh-Crestani G, Hrebien S, et al.
Nat Commun
. 2021 Jul;
12(1):4479.
PMID: 34272402
No abstract available.
16.
Kingston B, Cutts R, Bye H, Beaney M, Walsh-Crestani G, Hrebien S, et al.
Nat Commun
. 2021 Apr;
12(1):2423.
PMID: 33893289
The genomics of advanced breast cancer (ABC) has been described through tumour tissue biopsy sequencing, although these approaches are limited by geographical and temporal heterogeneity. Here we use plasma circulating...
17.
Baird R, Linossi C, Middleton M, Lord S, Harris A, Rodon J, et al.
J Clin Oncol
. 2020 Dec;
39(2):145-154.
PMID: 33301375
Purpose: A first-in-human study was performed with MP0250, a DARPin drug candidate. MP0250 specifically inhibits both vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) with the aim of...
18.
Ros S, Wright A, DSantos P, Hu D, Hesketh R, Lubling Y, et al.
Cancer Cell
. 2020 Sep;
38(4):516-533.e9.
PMID: 32976773
PIK3CA, encoding the PI3Kα isoform, is the most frequently mutated oncogene in estrogen receptor (ER)-positive breast cancer. Isoform-selective PI3K inhibitors are used clinically but intrinsic and acquired resistance limits their...
19.
Turner N, Kingston B, Kilburn L, Kernaghan S, Wardley A, Macpherson I, et al.
Lancet Oncol
. 2020 Sep;
21(10):1296-1308.
PMID: 32919527
Background: Circulating tumour DNA (ctDNA) testing might provide a current assessment of the genomic profile of advanced cancer, without the need to repeat tumour biopsy. We aimed to assess the...
20.
Macpherson I, Spiliopoulou P, Rafii S, Saggese M, Baird R, Garcia-Corbacho J, et al.
Breast Cancer Res
. 2020 Jan;
22(1):1.
PMID: 31892325
Background: Epertinib (S-222611) is a potent reversible inhibitor of HER2, EGFR and HER4. This trial evaluated the safety, tolerability, pharmacokinetics and antitumour activity of daily oral epertinib combined with trastuzumab...